Garden State Investment Advisory Services LLC Makes New $1.64 Million Investment in MeiraGTx Holdings plc (NASDAQ:MGTX)

Garden State Investment Advisory Services LLC acquired a new stake in MeiraGTx Holdings plc (NASDAQ:MGTX) during the 3rd quarter, Holdings Channel reports. The institutional investor acquired 392,400 shares of the company’s stock, valued at approximately $1,636,000.

A number of other hedge funds also recently made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in MeiraGTx in the 2nd quarter valued at $123,000. Letko Brosseau & Associates Inc. increased its holdings in shares of MeiraGTx by 38.5% in the second quarter. Letko Brosseau & Associates Inc. now owns 45,300 shares of the company’s stock valued at $191,000 after purchasing an additional 12,600 shares during the last quarter. Knoll Capital Management LLC acquired a new position in shares of MeiraGTx in the third quarter valued at $5,212,000. American Century Companies Inc. raised its position in shares of MeiraGTx by 42.4% in the second quarter. American Century Companies Inc. now owns 40,008 shares of the company’s stock valued at $168,000 after purchasing an additional 11,907 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of MeiraGTx by 14.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 462,950 shares of the company’s stock worth $1,949,000 after buying an additional 58,854 shares during the last quarter. 67.48% of the stock is owned by institutional investors and hedge funds.

MeiraGTx Stock Performance

Shares of MeiraGTx stock opened at $6.77 on Monday. The company’s 50 day moving average price is $5.54 and its two-hundred day moving average price is $4.87. The firm has a market capitalization of $529.08 million, a P/E ratio of -5.60 and a beta of 1.24. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34. MeiraGTx Holdings plc has a fifty-two week low of $3.85 and a fifty-two week high of $7.60.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Royal Bank of Canada lifted their price target on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Chardan Capital restated a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a research report on Monday, November 18th.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.